Outcomes of Human Papilloma Virus Vaccination in a Private Women Health Clinic in Lebanon
Table 2
Cervical cytology screening in women who were not initially sexually active and received the human papilloma virus vaccine at the Women’s Health Center (WHC) of the American University of Beirut-Medical Center (AUBMC) 2007–2017.
Bivalent vaccine
Quadrivalent vaccine
Total
value
Age at vaccination (years)
Mean ± SD
25.9 ± 4.9
28 ± 4.7
27.7 ± 4.7
0.003
Median (range)
25 (17–38)
27 (18–45)
27 (17–45)
N (%)
48 (18%)
219 (82%)
267
% Of ladies >25 years old at first dose of vaccination
47.9%
70.3%
66.3%
0.003
(23/48)
(154/219)
(177/267)
Age at first pap smear after vaccination (years)
Mean
27.7 ± 3.9
29.2 ± 5.0
29.0 ± 4.9
0.057
Median (range)
28 (18–38)
28 (19–46)
28 (18–46)
N
48
219
267
% Of ladies >25 years old at first Pap smear
70.8%
79%
77.5%
0.25
(34/48)
(173/219)
(207/267)
Incidence of abnormal Pap smear postvaccination
N (%)
(4/48) 8%
(10/267) 4.6%
(14/267) 5%
0.022
Age at abnormal pap smear postvaccine (years)
Mean
31.3 ± 3.9
32 ± 4.0
32 ± 3.9
0.637
Median (range)
32 (26–35)
32 (26–40)
32 (26–40)
% Of females >25 years old at time of vaccination with subsequent abnormal Pap smear
50% (2/4)
60% (6/10)
57.1% (8/14)
0.733
Subsequent Pap smear results following HPV vaccination
